Victoza for weight loss: what day-two side effects actually tell you

What did @libinbloom actually say?

On day two of her first Victoza (liraglutide) dose, the creator described nausea, vomiting, and upset stomach, then flagged something unusual: "my chin is numb." Her doctor told her the numbness was concerning enough that worsening symptoms would warrant a hospital visit due to possible tongue or throat swelling. The creator then reframed this as "all normal side effects" and decided to push through.

To be clear about the sequence: the doctor expressed concern and set a conditional threshold for escalation. The creator then compressed that nuanced warning into reassurance. That compression matters, and we will get into why below.

Does the science back this up?

The GI side effects are well-documented. The nausea and vomiting are not in dispute. The chin numbness is a different story entirely.

Liraglutide's prescribing information and the landmark LEADER trial (Marso et al., 2016, NEJM) document nausea in roughly 28 percent of users and vomiting in about 11 percent. These are dose-dependent and typically peak in the first few weeks. That part of the creator's experience is textbook.

Facial numbness, however, does not appear in the standard adverse event profile for GLP-1 receptor agonists. The more serious concern her doctor raised, tongue or throat swelling, points toward angioedema, a rare but serious allergic reaction. The FDA label for liraglutide lists angioedema as a post-marketing adverse event. A pharmacovigilance review by Drucker (2018, Cell Metabolism) notes that while allergic reactions to GLP-1 agents are uncommon, they are not negligible, particularly in patients with autoimmune conditions. The creator has IgA nephropathy, an autoimmune kidney disease, which makes this flag more, not less, relevant.

What did they get wrong (or right)?

Credit where it is due: she called her doctor same day, which is the right move. Her doctor's guidance was appropriately cautious.

Where things go sideways is the conclusion the creator drew. Describing chin numbness and a conditional hospital referral as "nothing serious" is inaccurate framing. Facial numbness following a new injectable medication is not a routine GI complaint. It is a neurological or vascular signal that clinicians take seriously because it can precede angioedema, stroke-adjacent symptoms, or injection-related nerve compression if the shot was given incorrectly.

The creator also said "most people can't get through side effects," attributing this to her doctor. That is an overstatement. Clinical trial data from the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed discontinuation due to adverse events in about 9 percent of liraglutide users versus 4 percent on placebo. That is a meaningful gap, but it does not mean most people fail to tolerate the drug.

What should you actually know?

Chin or facial numbness after starting a GLP-1 drug is not listed as an expected side effect and should not be dismissed. If your doctor says "go to the hospital if this gets worse," that is a conditional warning, not a green light to continue as planned.

A few practical points worth knowing. First, IgA nephropathy involves immune dysregulation, and while liraglutide is not contraindicated in this population, the intersection of autoimmune disease and a new drug reaction deserves closer monitoring than average. Second, the "push through" advice is clinically appropriate for nausea and vomiting, not for unexplained facial numbness. Those are categorically different symptoms. Third, injection technique matters. Liraglutide is a subcutaneous injection. Incorrect placement near nerve-dense tissue could theoretically cause localized numbness, though chin involvement after an abdominal or thigh injection would still be unusual and worth documenting.

If you are starting a GLP-1 medication and experience any facial numbness, swelling of the lips, tongue, or throat, or difficulty breathing, do not wait to see if it gets worse. That is the scenario the creator's own doctor was flagging.